Valuing the health states associated with chlamydia trachomatis infections and their sequelae: A systematic review of economic evaluations and primary studies

Value in Health

Volumn 17, Issue 1, 2014, Pages 116-130

  Jackson, Louise J ^a   Auguste, Peter ^b   Low, Nicola ^c   Roberts, Tracy E ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

chlamydia; economic evaluation; health states; infectious diseases; valuation

Indexed keywords

ARTICLE; CHLAMYDIASIS; COST; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; ECTOPIC PREGNANCY; HEALTH STATUS; HUMAN; INFERTILITY; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

CHLAMYDIA; ECONOMIC EVALUATION; HEALTH STATES; INFECTIOUS DISEASES; VALUATION;

CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COST-BENEFIT ANALYSIS; HEALTH STATUS; HUMANS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84892611794     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.10.005     Document Type: Article

References (86)

1. J.E. Brazier, D. Rowen, and I. Mavranezouli et al. Developing and testing methods for deriving preference-based measures of health from condition-specific measures (and other patient-based measures of outcome) Health Technol Assess 16 2012 1 113
2. E. Nicod, and P. Kanavos Commonalities and differences in HTA outcomes: a comparative analysis of five countries and implications for coverage decisions Health Policy 108 2012 167 177
3. M.R. Gold, J.E. Siegel, L.B. Russell, and M.C. Weinstein Cost-Effectiveness in Health and Medicine 1996 Oxford University Press New York
4. J. Brazier, J. Ratcliffe, and J. Salomon Measuring and Valuing Health Benefits for Economic Evaluation 2007 Oxford University Press Oxford, UK
5. J. Brazier Valuing health states for use in cost-effectiveness analysis Pharmacoeconomics 26 2008 769 779
6. R. Ara, and W. Allan Using health state utility values in models exploring the cost-effectiveness of health technologies Value Health 15 2012 971 974
7. T.O. Tengs, and A. Wallace One thousand health-related quality-of-life estimates Med Care 38 2000 583 637
8. W.J. Ungar Challenges in health state valuation in paediatric economic evaluation Pharmacoeconomics 29 2011 641 652
9. S. Banerjee, K. Samsi, and C.D. Petrie et al. What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia Int J Geriatr Psychiatry 24 2009 15 24
10. M.F. Drummond, M.J. Sculpher, and G.W. Torrance et al. Methods for the Economic Evaluation of Health Care Programs 2005 Oxford University Press Oxford, UK
11. R. Ara, and JE Brazier Populating an economic model with health state utility values: moving toward better practice Value Health 13 2010 509 518
12. M. Roberts, L.B. Russell, and A.D. Paltiel et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2 Med Decis Making 32 2012 678 689
13. A.H. Briggs, M.C. Weinstein, and E.A. Fenwick et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force Working Group-6 Med Decis Making 32 2012 722 732
14. A.H. Briggs, K. Claxton, and M.J. Sculpher Decision Modelling for Health Economic Evaluation 2006 Oxford University Press New York
15. National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. 2013. Available from: http://www.nice.org.uk/ media/D45/1E/GuideToMethodsTechnologyAppraisal2013.pdf. [Accessed May 10, 2013].
16. National Institute for Health and Care Excellence. Methods for the Development of NICE Public Health Guidance (3rd ed.). Available from: http://publications.nice.org.uk/methods-for-the-development-of-nice-public- health-guidance-third-edition-pmg4. [Accessed September 24, 2013].
17. T.E. Roberts, S. Robinson, and P. Barton et al. Screening for Chlamydia trachomatis: a systematic review of the economic evaluations and modelling Sex Transm Infect 82 2006 193 200
18. E. Honey, C. Augood, and A. Templeton et al. Cost effectiveness of screening for Chlamydia trachomatis: a review of published studies Sex Transm Infect 78 2002 406 412
19. T.L. Gift, D.R. Blake, C.A. Gaydos, and J.M. Marrazzo The cost-effectiveness of screening men for Chlamydia trachomatis: a review of the literature Sex Transm Dis 35 2008 S51 S60
20. World Health Organization. Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections 2008. Available from: http://www.who.int/reproductivehealth/publications/rtis/stisestimates/en/index. html. [Accessed May 10, 2013].
21. Public Health England Health Protection Report. Sexually transmitted infections and chlamydia screening in England, 2012. 2013. Available from: http://www.hpa.org.uk/hpr/infections/hiv-sti.htm#stis. [Accessed June 8, 2013].
22. K.A. Fenton, C. Korovessis, and A.M. Johnson et al. Sexual behaviour in Britain: reported sexually transmitted infections and prevalent genital Chlamydia trachomatis infection Lancet 358 2001 1851 1854
23. S.D. Datta, E. Torrone, and D. Kruszon-Moran et al. Chlamydia trachomatis trends in the United States among persons 14 to 39 years of age, 1999-2008 Sex Transm 39 2012 92 96
24. I. Bozicevic, I. Grgic, and S. Zidovec-Lepej et al. Urine-based testing for Chlamydia trachomatis among young adults in a population-based survey in Croatia: feasibility and prevalence BMC Public Health 11 2011 230
25. W.E. Stamm Chlamydia trachomatis infections in the adult K.K. Holmes, P.F. Sparling, W.E. Stamm, Sexually Transmitted Diseases 4th ed. 2008 McGraw-Hill Medical New York 575 594
26. C.L. Althaus, J. Heijne, A. Roellin, and N. Low Transmission dynamics of Chlamydia trachomatis affect the impact of screening programmes Epidemics 2 2010 123 131
27. S.A. Herzog, C.L. Althaus, and J.C. Heijne et al. Timing of progression of Chlamydia trachomatis infection to pelvic inflammatory disease: a mathematical modelling study BMC Infect Dis 12 2012 187
28. P. Oakeshott, S. Kerry, and A. Aghaizu et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (Prevention of Pelvic Infection) trial BMJ 340 2010 c1642
29. M.J. Price, A.E. Ades, and D. De Angelis et al. Risk of pelvic inflammatory disease following Chlamydia trachomatis infection: analysis of prospective studies with a multistate model Am J Epidemiol 178 2013 484 492
30. S.L. Gottlieb, R.C. Brunham, and G.I. Byrne et al. Introduction: the natural history and immunobiology of Chlamydia trachomatis genital infection and implications for chlamydia control J Infect Dis 201 Suppl. 2010 S85 S87
31. C.L. Haggerty, S.L. Gottlieb, and B.D. Taylor et al. Risk of sequelae after Chlamydia trachomatis genital infection in women J Infect Dis 201 2010 S134 S155
32. D. Baud, L. Regan, and G. Greub Emerging role of Chlamydia and Chlamydia-like organisms in adverse pregnancy outcomes Curr Opin Infect Dis 21 2008 70 76
33. M.R. Hammerschlag Chlamydial and gonococcal infections in infants and children Clin Infect Dis 53 Suppl. 2011 S99 102
34. I. Mylonas Female genital Chlamydia trachomatis infection: where are we heading? Arch Gynecol Obstet 285 2012 1271 1285
35. N. Mills, G. Daker-White, A. Graham, and R. Campbell Population screening for Chlamydia trachomatis infection in the UK: a qualitative study of the experiences of those screened Fam Pract 23 2006 550 557
36. J. Darroch, L. Myers, and J. Cassell Sex differences in the experience of testing positive for genital chlamydia infection: a qualitative study with implications for public health and for a national screening programme Sex Transm Infect 79 2003 372 373
37. S.L. Gottlieb, F. Xu, and R.C. Brunham Screening and treating Chlamydia trachomatis genital infection to prevent pelvic inflammatory disease: interpretation of findings from randomized controlled trials Sex Transm Dis 40 2013 97 102
38. S.A. Herzog, J.C.M. Heijne, C.L. Althaus, and N. Low Describing the progression from Chlamydia trachomatis and Neisseria gonorrhoeae to pelvic inflammatory disease: systematic review of mathematical modeling studies Sex Transm Dis 39 2012 628 637
39. L.R. Schover Motivation for parenthood after cancer: a review J Natl Cancer Inst Monogr 34 2005 2 5
40. J. Carter Cancer-related infertility Gynecol Oncol 99 Suppl. 2005 S122 S123
41. S.Z. Jia, J.H. Leng, and J.H. Shi et al. Health-related quality of life in women with endometriosis: a systematic review J Ovar Res 5 2012 1 9
42. L. Westrom, R. Joesoef, and G. Reynolds et al. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results Sex Transm Dis 19 1992 185 192
43. R.B. Ness, D.E. Soper, and H.E. Richter et al. Chlamydia antibodies, chlamydia heat shock protein, and adverse sequelae after pelvic inflammatory disease: The PID Evaluation and Clinical Health (PEACH) study Sex Transm Dis 35 2008 129 135
44. D.R. Wright, E. Wittenberg, and J.S. Swan et al. Methods for measuring temporary health states for cost-utility analyses Pharmacoeconomics 27 2009 713 723
45. S. Frederick, G. Loewenstein, and T. O'Donoghue Time discounting and time preference: a critical review J Econ Lit 40 2002 351 401
46. A.E. Attema, and W.B. Brouwer The value of correcting values: influence and importance of correcting TTO scores for time preference Value Health 13 2010 879 884
47. P. Dolan Whose preferences count? Med Decis Making 19 1999 482 486
48. P. Dolan Developing methods that really do value the Q in the QALY Health Econ Policy Law 3 2008 69 77
49. D. Moher, A. Liberati, and J. Tetzlaff et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 4 2009 264 269
50. Centre for Reviews and Dissemination, University of York. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. York: Centre for Reviews and Dissemination, University of York, 2009. Available from: http://www.york.ac.uk/inst/crd/pdf/Systematic-Reviews.pdf. [Accessed November 22, 2012].
51. T. Roberts, J. Henderson, and M. Mugford et al. Antenatal ultrasound screening for fetal abnormalities: a systematic review of studies of cost and cost effectiveness Br J Obstet Gynaecol 109 2002 44 56
52. K.J. Smith, R.L. Cook, and M.S. Roberts Time from sexually transmitted infection acquisition to pelvic inflammatory disease development: influence on the cost-effectiveness of different screening intervals Value Health 10 2007 358 366
53. D.P. Wilson, K.J. Heymer, and J. Anderson et al. Sex workers can be screened too often: a cost-effectiveness analysis in Victoria, Australia Sex Transm Infect 86 2010 117 125
54. T.L. Gift, C.A. Gaydos, and C.K. Kent et al. The program cost and cost-effectiveness of screening men for chlamydia to prevent pelvic inflammatory disease in women Sex Transm Dis 35 Suppl. 2008 S66 S75
55. J.L. Burgos, J.A. Gaebler, and S.A. Strathdee et al. Cost-effectiveness of an intervention to reduce HIV/STI incidence and promote condom use among female sex workers in the Mexico-US border region Plos One 5 2010 e11413
56. E.J. Adams, K.M.E. Turner, and W.J. Edmunds The cost effectiveness of opportunistic chlamydia screening in England Sex Transm Infect 83 2007 267 275
57. J.E. Aledort, E.W. Hook, M.C. Weinstein, and S.J. Goldie The cost effectiveness of gonorrhea screening in urban emergency departments Sex Transm Dis 32 2005 425 436
58. R. De Vries, and J. Van Bergen De Jong-van den Berg L, Postma M. Cost-utility of repeated screening for Chlamydia trachomatis Value Health 11 2008 272 274
59. P. Gillespie, C. O'Neill, and E. Adams et al. The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland Sex Transm Infect 88 2012 222 228
60. D. Hu, E.W. Hook, and S.J. Goldie Screening for Chlamydia trachomatis in women 15 to 29 years of age: a cost-effectiveness analysis Ann Intern Med 141 2004 501 513
61. D. Hu, E.W. Hook, and S.J. Goldie The impact of natural history parameters on the cost-effectiveness of Chlamydia trachomatis screening strategies Sex Transm Dis 33 2006 428 436
62. S. Walleser, G. Salkeld, and B. Donovan The cost effectiveness of screening for genital Chlamydia trachomatis infection in Australia Sex Health 3 2006 225 234
63. K.J. Smith, R.B. Ness, H.C. Wiesenfeld, and M.S. Roberts Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies Sex Transm Dis 34 2007 960 966
64. K.J. Smith, R.B. Ness, and M.S. Roberts Hospitalization for pelvic inflammatory disease: a cost-effectiveness analysis Sex Transm Dis 34 2007 108 112
65. J. Shepherd, J. Kavanagh, and J. Picot et al. The effectiveness and cost-effectiveness of behavioural interventions for the prevention of sexually transmitted infections in young people aged 13-19: a systematic review and economic evaluation Health Technol Assess 14 2010 1 118
66. C.L. Deogan, M.K.H. Bocangel, S.P. Wamala, and A.M. Mansdotter A cost-effectiveness analysis of the Chlamydia Monday - a community-based intervention to decrease the prevalence of chlamydia in Sweden Scand J Public Health 38 2010 141 150
67. A.R. Tuite, G.C. Jayaraman, V.G. Allen, and D.N. Fisman Estimation of the burden of disease and costs of genital Chlamydia trachomatis infection in Canada Sex Transm Dis 39 2012 260 267
68. J.M. Yeh, E.W. Hook, and S.J. Goldie A refined estimate of the average lifetime cost of pelvic inflammatory disease Sex Transm Dis 30 2003 369 378
69. T. Gift, P. Kissinger, and H. Mohammed et al. The cost of expedited partner therapy compared to the cost of standard partner referral for the treatment of chlamydia or gonorrhoea Sex Transm Infect 87 2011 A62
70. F.A. Sonnenberg, R.T. Burkman, and C.G. Hagerty et al. Costs and net health effects of contraceptive methods Contraception 69 2004 447 459
71. K.J. Smith, J. Tsevat, and R.B. Ness et al. Quality of life utilities for pelvic inflammatory disease health states Sex Transm Dis 35 2008 307 311
72. M. Trent, H.P. Lehmann, and Q. Qian et al. Adolescent and parental utilities for the health states associated with pelvic inflammatory disease Sex Transm Infect 87 2011 583 587
73. Institute of Medicine Vaccines for the 21st Century: A Tool for Decisionmaking 1999 National Academy Press Washington
74. M. Kuppermann, L.A. Learman, and M. Schembri et al. Effect of noncancerous pelvic problems on health-related quality of life and sexual functioning Obstet Gynecol 110 2007 633 642
75. T.J. Songer, J.R. Lave, and M.S. Kamlet et al. Preferences for fertility in women with pelvic inflammatory disease Fertil Steril 81 2004 1344 1350
76. L.A. Prosser, S.D. Grosse, and E. Wittenberg Health utility elicitation: is there still a role for direct methods? Pharmacoeconomics 30 2012 83
77. N.K. LoConte, N.M. Else-Quest, and J. Eickhoff et al. Assessment of guilt and shame in patients with non-small-cell lung cancer compared with patients with breast and prostate cancer Clin Lung Cancer 9 2008 171 178
78. S. Herrmann, E. McKinnon, and N.B. Hyland et al. HIV-related stigma and physical symptoms have a persistent influence on health-related quality of life in Australians with HIV infection Health Qual Life Outcomes 11 2013 1 13
79. I. Margalith, G. Gillon, and D. Gordon Urinary incontinence in women under 65: quality of life, stress related to incontinence and patterns of seeking health care Qual Life Res 13 2004 1381 1390
80. J. Waller, L.A. Marlow, and J. Wardle The association between knowledge of HPV and feelings of stigma, shame and anxiety Sex Transm Infect 83 2007 155 159
81. B. Mulhern, D. Rowen, and A. Jacoby et al. The development of a QALY measure for epilepsy: NEWQOL-6D Epilepsy Behav 24 2012 36 43
82. M.V. Bala, L.L. Wood, and G.A. Zarkin et al. Are health states timeless? The case of the standard gamble method J Clin Epidemiol 52 1999 1047 1053
83. A. Tsuchiya, and P. Dolan The QALY model and individual preferences for health states and health profiles over time: a systematic review of the literature Med Decis Making 25 2005 460 467
84. Pharmaceutical Benefits Advisory Committee. Guidelines for Preparing Submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). Canberra, Australia: Australian Government Department of Health and Ageing, 2008. Available from: http://www.health.gov.au/internet/main/publishing.nsf/ Content/pbacguidelines-index. [Accessed May 10, 2013].
85. Althaus C., Turner K.M.C., Mercer C., et al. Clinical and cost-effectiveness of traditional and new partner notification technologies for curable sexually transmitted infections. Health Technol Assess. In press.
86. T.L. Gift, and C.J. Owens The direct medical cost of epididymitis and orchitis: evidence from a study of insurance claims Sex Transm Dis 33 Suppl 2006 S84 S88